홈/주식/RCUS
RCUS

RCUS

USD

Arcus Biosciences Inc. Common Stock

$19.830+0.130 (0.660%)

실시간 가격

Healthcare
생명공학
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$19.700

고가

$20.500

저가

$19.691

거래량

0.41M

기업 기본 정보

시가총액

2.4B

산업

생명공학

국가

United States

거래 통계

평균 거래량

1.18M

거래소

NYQ

통화

USD

52주 범위

저가 $6.5현재가 $19.830고가 $22.11

관련 뉴스

BusinessWire

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune

더 보기
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Analyst Upgrades

Goldman Sachs Maintains Neutral on Arcus Biosciences, Raises Price Target to $16

Goldman Sachs analyst Salveen Richter maintains Arcus Biosciences with a Neutral and raises the price target from $14 to $16.

더 보기
Goldman Sachs Maintains Neutral on Arcus Biosciences, Raises Price Target to $16
Analyst Upgrades

Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $56

Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences with a Buy and raises the price target from $54 to $56.

더 보기
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $56
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $28

HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences with a Buy and raises the price target from $24 to $28.

더 보기
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $28
BusinessWire

Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update

Casdatifan, a potential best-in-class HIF-2a inhibitor, demonstrated 12.2 months median progression-free survival (mPFS) and 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late-line kidney

더 보기
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
Analyst Upgrades

Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $54

Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences with a Buy and raises the price target from $47 to $54.

BusinessWire

Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study

First overall survival (OS) results from Arm A1 of the Phase 2 EDGE-Gastric study will be presented on October 18 at the European Society for Medical Oncology (ESMO) 2025 Congress These data support the ongoing

최신 정보 받기

가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기